Koios Beverage Corp. (CSE: FIT; OTC: FITSF) (the "Company"
or "Koios") is pleased to announce that its KOIOS™
nootropic functional beverages have been approved for placement and
are now available in over 600 CVS locations in Texas, Tennessee,
Missouri, New Jersey, California, Florida, Indiana and New York.
CVS Pharmacy is a subsidiary of CVS Health Corp. (NYSE: CVS),
the 4th largest U.S. corporation by FY2021 revenues in the Fortune
5001. In 2021, it reported $292.1 billion in revenue2.
CVS has over 9000 retail locations, approximately 256,000
employees, and serves 4.5 million retail pharmacy customers daily3.
It is the largest pharmacy chain in the United States by number of
locations and prescription revenue.
"We are thrilled to be working with the largest retail pharmacy
in the country," said Koios CEO and founder Chris Miller. "CVS is
leading the charge in health solutions for the world, and we’re
excited for our brand’s functional and healthy beverages to be a
part of that. Our mission is to make the world a healthier place
and our partnership with CVS will help us succeed in this.”
To date in 2022, Koios has announced that its functional
beverages have been approved for placement at United Supermarkets,
a subsidiary of Albertsons, Ingles Markets, Tony’s Fresh
Market, Raley’s, and Harris Teeter. The Company’s effort to
place its KOIOS™ and Fit Soda™ beverages in regional and national
grocery chains is part of a strategy to gain new placements in more
national chains.
Miller continues, “Partnering with CVS is part of our strategy
to continue placing our products in the biggest retailers in the
world to expand our market footprint. Growth for Koios is high
right now and we expect to continue seeing growth at a rapid pace
as we gain momentum across the marketplace.”
With approval for KOIOS™ beverages to be sold in CVS, new
placements could be more rapidly finalized and enable the Company
to further grow its base of more than 6,000 retail locations in the
United States.
On behalf of the Board of Directors of the Company,
KOIOS BEVERAGE CORP.
“Chris Miller”
Chris Miller, CEO, and Director
For further information, please contact:
Gina Burrus
844-255-6467
gina@koiosbeveragecorp.com
THE CANADIAN SECURITIES EXCHANGE (CSE) HAS NOT REVIEWED AND DOES
NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS
RELEASE.
About Koios Beverage Corp.
The Company is an emerging functional beverage company which has
an available distribution network of more than 4,400 retail
locations across the United States in which to sell its products.
Koios has relationships with some of the largest and most reputable
distributors in the United States, including Europa Sports, Muscle
Foods USA, KeHE, and Wishing-U-Well. Koios uses a proprietary blend
of nootropics and natural organic compounds to enhance human
productivity without using harmful chemicals or stimulants. Koios
products have been shown to enhance focus, concentration, mental
capacity, memory retention, cognitive function, alertness, brain
capacity and create all day mental clarity. Its ingredients are
specifically designed to target brain function by increasing blood
flow, oxygen levels and neural connections in the brain.
Koios produces one of the only drinks in the world infused with
MCT oil. MCT oil is derived from coconuts and has been shown to
help the body burn fat more effectively, create lasting energy from
a natural food source, produce ketones in the brain, allowing for
greater brain function and clarity, support healthy hormone
production and improve immunity. For more information, please visit
our website: https://www.koiosbeveragecorp.com.
Forward-Looking Statements
This news release contains “forward-looking information” within
the meaning of applicable Canadian securities legislation. Often,
but not always, forward-looking information and information can be
identified by the use of words such as “plans”, “expects” or “does
not expect”, “is expected”, “estimates”, “intends”, “anticipates”
or “does not anticipate”, or “believes”, or variations of such
words and phrases or state that certain actions, events or results
“may”, “could”, “would”, “might” or “will” be taken, occur or be
achieved. Forward-looking information in this news release includes
statements regarding: Potential outcomes from the placement of
KOIOS™ nootropic functional beverages in over 600 CVS Locations and
the overall performance of the functional beverage market. The
forward-looking information reflects management's current
expectations based on information currently available and are
subject to a number of risks and uncertainties that may cause
outcomes to differ materially from those discussed in the
forward-looking information. Although the Company believes that the
assumptions and factors used in preparing the forward-looking
information are reasonable, undue reliance should not be placed on
such information and no assurance can be given that such events
will occur in the disclosed time frames or at all. Factors that
could cause actual results or events to differ materially from
current expectations include: (i) adverse market conditions; (ii)
changes to the growth and size of the functional beverage markets;
and (iii) other factors beyond the control of the Company. The
Company operates in a rapidly evolving environment. New risk
factors emerge from time to time, and it is impossible for the
Company’s management to predict all risk factors, nor can the
Company assess the impact of all factors on Company’s business or
the extent to which any factor, or combination of factors, may
cause actual results to differ from those contained in any
forward-looking information. The forward-looking information
included in this news release are made as of the date of this news
release and the Company expressly disclaims any intention or
obligation to update or revise any forward-looking information
whether as a result of new information, future events or otherwise,
except as required by applicable law.
The statements in this news release have not been evaluated by
Health Canada or the U.S. Food and Drug Administration. As each
individual is different, the benefits, if any, of taking the
Company’s products will vary from person to person. No claims or
guarantees can be made as to the effects of the Company’s products
on an individual's health and well-being. The Company’s products
are not intended to diagnose, treat, cure, or prevent any
disease.
This news release may contain trademarked names of third-party
entities (or their respective offerings with trademarked names)
typically in reference to (i) relationships had by Koios with such
third-party entities as referred to in this release and/or (ii)
client/vendor/service provider parties whose relationship with
Koios is/are referred to in this release. All rights to such
trademarks are reserved by their respective owners or
licensees.
1 Fortune 5002 Fortune 500: CVS Health3 CVS: Our Company At A
Glance
CVS Health (NYSE:CVS)
Historical Stock Chart
From Apr 2024 to May 2024
CVS Health (NYSE:CVS)
Historical Stock Chart
From May 2023 to May 2024